8-K
filed April 26, 2023, 7:59 PM ET
ticker ALZN
CIK 0001677077
other material
confidence high
sentiment neutral
materiality 0.15
Alzamend Neuro announces 2023 annual meeting voting results; all proposals pass
Alzamend Neuro, Inc.
- Elected directors: Horne, Jackman, Nisser, Gustafson, McGrath, Woo, Oram; each received >46.6M votes for.
- Advisory vote on executive compensation approved: 48.4M for, 1.3M against.
- Say-on-frequency set to every 3 years (39.7M votes for 3 years); next advisory vote in 2026.
- Ratification of Baker Tilly US, LLP as auditor for FY ending April 30, 2023 approved: 49.6M for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alzamend Neuro, Inc. shareholders approved Election of Directors at the 2023-04-26 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-04-26
Exact text from the filing
The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2024 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: For Against Abstain Broker Non-Votes William B. Horne 48,331,149 1,608,194 101,645 0 Stephan Jackman 48,764,875 932,276 343,837 0 Henry C.W. Nisser 48,356,036 1,331,634 353,318 0 Mark Gustafson 49,173,713 519,189 348,086 0 Lynne F. McGrath 48,800,233 890,218 350,537 0 Andrew H. Woo 49,165,224 527,277 348,487 0 Jeffrey Oram 46,688,974 2,996,276 355,738 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alzamend Neuro, Inc. shareholders approved Ratification of the Independent Registered Public Accounting Firm at the 2023-04-26 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-04-26
Exact text from the filing
The stockholders ratified the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2023. For Against Abstain Broker Non-Votes 49,628,290 331,775 80,923 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alzamend Neuro, Inc. shareholders approved Advisory Vote on Frequency of Future Advisory Votes on Named Executive Officer Compensation at the 2023-04-26 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-04-26
Exact text from the filing
The stockholders approved, on a non-binding advisory basis, the frequency of the stockholder vote to approve the compensation of the Company’s Named Executive Officers as described in the Proxy Statement as follows: 3 Years 2 Years 1 Year Abstain Broker Non-Votes 39,734,366 712,873 9,530,011 63,738 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Alzamend Neuro, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2023-04-26 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-04-26
Exact text from the filing
The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the executive compensation tables contained in the Proxy Statement. For Against Abstain Broker Non-Votes 48,354,282 1,332,190 354,516 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.